A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of TAC-101 [amsilarotene] in Combination With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 27 Jan 2016
At a glance
- Drugs Amsilarotene (Primary) ; Antineoplastics
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 10 Jun 2017 Biomarkers information updated
- 21 Mar 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 17 Mar 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.